Guillermo Villacampa: The safety and efficacy of ADCs with immunotherapy

Guillermo Villacampa, Biostatistician, Vall d´Hebron Institute of Oncology (VHIO), shared a post on X:

“Antibody-drug conjugate (ADCs) in combination with immunotherapy is emerging as a promising strategy. However, concerns arise regarding the safety.

In this work, we present a combined analysis evaluating the safety and efficacy of this combination.”

Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis

Authors: Guillermo Villacampa, Pablo Cresta Morgado, Lorenzo Carità, Victor Navarro, Tomas Pascual and Rodrigo Dienstmann.